

1. Record Nr.	UNINA9910488724503321
Titolo	Essentials of tissue and cells banking // George Galea, Marc Turner and Sharon Zahra (editors)
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2021] ©2021
ISBN	3-030-71621-X
Edizione	[Second edition.]
Descrizione fisica	1 online resource (288 pages)
Disciplina	362.1783
Soggetti	Tissue banks Procurement of organs, tissues, etc Preservation of organs, tissues, etc Bancs de teixits Conservació de teixits (Biologia) Conservació d'òrgans Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Intro -- Preface -- Contents -- 1 Live Donors of Tissue -- Abstract -- 1.1 Introduction -- 1.2 Regulation -- 1.3 Donor Identification -- 1.3.1 Femoral Head Donation -- 1.3.2 Amniotic Membrane Donation -- 1.4 Consent -- 1.5 Donor Selection: Evidence Base and General Considerations -- 1.6 Generic Contraindications -- 1.6.1 Transmissible Infections -- 1.6.2 Acute Infections -- 1.6.3 Risk of Transmission of Prion Diseases -- 1.6.4 Malignancy -- 1.7 Retrieval/Procurement -- 1.8 Summary -- References -- 2 Deceased Tissue Donors -- Abstract -- 2.1 Introduction -- 2.2 Deceased Tissue Donor Identification -- 2.3 The Law and the Role of the Family -- 2.4 Age Cut-Offs -- 2.5 Medical, Behavioural and Social Assessment -- 2.6 Blood Sampling and Haemodilution -- 2.7 Timing and Venue of Retrieval -- 2.8 Retrieval Process -- 2.9 Conclusion -- References -- 3 Banking and Use of Umbilical Cord Blood -- Abstract -- 3.1 Introduction -- 3.2 Donation Programmes -- 3.2.1 Collection Sites -- 3.2.2 Recruitment and Consent -- 3.2.3 Donor Eligibility -- 3.2.4 Collection Techniques --

3.2.5 Donor Follow up -- 3.2.6 Non-Frozen Transportation -- 3.3
 Umbilical Cord Blood Processing and Storage -- 3.3.1 Banking
 Structure and Resources -- 3.3.2 Reception and Process Acquisition --
 3.3.3 Volume Reduction -- 3.3.4 Cryopreservation -- 3.3.5 Testing and
 Product Conformity -- 3.3.6 Inventory Management -- 3.4 Use of
 Umbilical Cord Blood for Transplantation -- 3.4.1 Selection Principles
 -- 3.4.2 Request for Shipping -- 3.4.3 Frozen Transportation -- 3.4.4
 Thawing and Infusion -- 3.4.5 Transplantation Outcomes -- 3.5 Future
 Challenges for Umbilical Cord Blood Banking -- References -- 4 Ocular
 Tissue Banking -- Abstract -- 4.1 Eye Donation -- 4.2 Corneal
 Transplantation -- 4.3 Corneal Storage -- 4.4 Hypothermia -- 4.5
 Organ Culture -- 4.6 Limbal Stem Cells.
 4.7 Extending the Role of Eye Banks -- 4.8 Other Cell-Based Therapies
 for Ocular Disease -- References -- 5 Banking of Heart Valves --
 Abstract -- 5.1 Introduction -- 5.2 Selection Criteria -- 5.3 Processing
 and Disinfection of Heart Valves -- 5.4 Quality Assurance of Heart
 Valves -- 5.5 Current Issues in Heart Valve Banking -- 5.5.1
 Mechanical Properties of Valves -- 5.6 Decellularization -- 5.7
 Vitrification -- 5.8 Matching of Valves -- 5.9 Centralised Supply --
 5.10 Conclusions -- References -- 6 Cryopreservation and Banking of
 Haematopoietic Progenitor Cells -- Abstract -- 6.1 Introduction -- 6.2
 Transportation of HPC Product from the Collection Site to Stem Cell
 Laboratory -- 6.3 Receipt and Initial Storage of HPC Products -- 6.4
 Preparation of HPC Products for Cryopreservation -- 6.5
 Cryopreservation of HPC Products -- 6.6 Rate of Freezing -- 6.7
 Storage of HPC Products -- 6.8 Transport of Frozen HPC Products --
 6.9 Further Processing Performed by Stem Cell Laboratories -- 6.9.1
 Bone Marrow (HPC,M) Processing -- 6.9.2 Selection/Depletion -- 6.9.3
 Campath in the Bag -- 6.10 Quality Control of the HPC Product -- 6.11
 Quality Control Post Cryopreservation -- 6.12 Conclusion --
 References -- 7 Storage, Processing and Preservation -- Abstract --
 7.1 Introduction -- 7.1.1 Tissue Replacement -- 7.1.2 Autologous
 Versus Allogeneic Grafts -- 7.1.3 Immunological Responses to Tissue
 Allografts -- 7.2 Principles of Tissue Preservation -- 7.2.1 Preservation
 of Non Viable Tissue Grafts -- 7.2.1.1 Causes of Degradation --
 7.2.1.2 Reduction of Water Activity -- Freeze-Drying (Lyophilisation) --
 Deep Freezing -- High Concentration Solutes -- 7.2.1.3 Cell Removal
 -- 7.2.2 Preservation of Viable Tissue Grafts -- 7.3 Principles of
 Disinfection and Sterilisation -- 7.3.1 Definitions -- 7.3.2 Disinfection
 Methods -- 7.3.2.1 Viable Tissues -- 7.3.2.2 Non-viable Tissues.
 7.3.3 Sterilisation Methods -- 7.3.3.1 Physical Methods -- 7.3.3.2
 Chemical Methods -- References -- 8 Cryopreservation in Tissue
 Banking -- Abstract -- 8.1 Introduction -- 8.2 Critical Impact of Ice
 Formation -- 8.3 The Role of Added Cryoprotectants -- 8.4 Sample
 Thawing -- 8.5 Spheroid and Organoid Cryopreservation -- 8.6 Toward
 the Cryopreservation of Organs and Biopsies -- 8.7 Quality Issues --
 8.8 Sterility, Handling and Contamination Issues -- 8.9 Conclusion --
 References -- 9 Sterilisation by Irradiation -- Abstract -- 9.1
 Introduction -- 9.2 Specificity of Radiation Sterilisation with Gamma
 Rays and Electron Beams -- 9.3 Dosimetry for Radiation Sterilisation --
 9.4 Mechanisms Involved in the Inactivation of Micro-organisms by
 Ionising Radiation -- 9.5 Radiation Resistance of Micro-organisms --
 9.6 Summary and Conclusions -- References -- 10 Screening the
 Tissue Donor for Infectious Agents -- Abstract -- 10.1 Introduction --
 10.2 Sample Quality -- 10.2.1 Living v. Deceased Donors -- 10.2.1.1
 Donor Selection -- 10.2.1.2 Laboratory Screening -- 10.2.2
 Haemodilution -- 10.2.3 Screening Targets -- 10.3 Range of Infectious
 Agents -- 10.3.1 Mandatory Screening -- 10.3.2 Additional/Selective

Screening -- 10.3.3 Screening for Other Infectious Agents -- 10.4
Emerging Infectious Threats -- 10.5 Screening Strategy -- 10.5.1
Screening Algorithms -- 10.6 Screening Assays -- 10.6.1 Serological
Screening Assays -- 10.6.2 Molecular Screening Assays -- 10.7
Residual Risk -- 10.7.1 Window Period -- 10.8 Conclusions --
References -- 11 Contamination in the Tissue Way -- Abstract -- 11.1
Introduction -- 11.1.1 Bacteria and Fungi -- 11.2 The Tissue Way, P.L.
C. Petit [22] -- 11.2.1 Donor -- 11.2.2 Tissue Retrieval in mortuary (1)
or operating theatre (2) -- 11.2.3 Transport -- 11.2.4 Tissue
Establishment -- 11.2.5 Microbiology Laboratory -- 11.3 Specific
Items.
11.4 Future -- References -- 12 Establishing a Quality System in a
Tissue Establishment -- 12.1 Background -- 12.2 The History of
Quality Management -- 12.3 Why a Quality Management System --
12.4 Why Quality? -- 12.5 What is Quality? -- 12.6 Examples of
Methods to Be Used in Quality -- 12.7 Available Standards and
International Legal Documents -- 12.8 Setting Up a Quality System --
12.9 Risk Management -- 12.10 Applying a Quality System to Your
Activities -- 12.10.1 Where Do I Start? -- 12.11 Biovigilance -- 12.12
Quality Systems and IT -- 12.13 Data Protection -- 12.14 The Cost of
Quality -- 12.14.1 The Cost of Quality Can Be Categorized into Four
Categories -- 12.15 Role of Management and Quality Management
Review -- 12.16 Conclusion -- References -- 13 IT System
Requirements for Tissue and Cell Banking -- Abstract -- 13.1
Introduction -- 13.2 Why Introduce an IT System? -- 13.3 The Benefits
of an IT System -- 13.4 What Are the Operational Requirements? --
13.5 Developing the Operational Requirements Document (ORD) --
13.5.1 Functional Requirements -- 13.5.2 Non-functional
Requirements -- 13.6 Technology Solutions -- 13.7 Managing the Data
-- 13.7.1 Barcodes -- 13.7.2 Radio Frequency Identification (RFID) --
13.7.3 OCR/ICR/Touch Screens -- 13.7.4 Electronic System Interfaces
-- 13.8 Database Management Technology -- 13.9 Selecting an IT
System -- 13.10 Cost of an IT System -- 13.11 Implementing an IT
System -- 13.11.1 Define Success -- 13.11.2 Set Priorities -- 13.11.3
Avoid Modifications -- 13.11.4 Prepare for Change -- 13.11.5 Gain
Executive Support -- 13.11.6 People -- 13.12 Implementation
Approach -- 13.13 System Validation -- 13.14 User Training -- 13.15
Managing an IT System -- 13.16 Conclusions -- References -- 14
Ethical and Regulatory Aspects of Cell and Tissue Banking -- Abstract
-- 14.1 Introduction -- 14.2 Ethical Issues.
14.2.1 Donor Consent -- 14.2.1.1 Types of Consent -- 14.2.1.2
Capacity to Consent -- Saviour Siblings -- Cord Blood -- 14.2.1.3
Informed Consent -- 14.2.2 Voluntary Donation -- 14.2.3 Property
Rights -- 14.2.3.1 Commercialisation -- 14.2.4 Confidentiality --
14.2.5 Certification of Death -- 14.2.6 Just Access -- 14.2.7 Safety
Issues -- 14.2.7.1 Infrastructure and Procedures -- 14.2.7.2
Healthcare Personnel -- 14.3 Societal Issues -- 14.3.1 Altruism --
14.3.2 Education -- 14.3.3 Cross-Border Exchange -- 14.3.4
Trafficking -- 14.4 Regulatory Instruments -- 14.4.1 Donor Consent --
14.4.2 Transplant Institutions -- 14.4.3 Data Protection -- 14.4.4
Training -- 14.5 Special Considerations for Cellular Therapies --
14.5.1 Capacity to Consent -- 14.5.2 Limits of Certainty of Consent --
14.5.3 Scope of Consent -- 14.5.4 Duration of Consent -- 14.5.5
Commercialisation -- 14.6 The Future -- 15 Human Embryonic Stem
Cell Banking for Clinical Applications-20 Years from Their Isolation --
Abstract -- 15.1 Introduction -- 15.2 Human Embryonic Versus
Induced Pluripotent Stem Cells as Clinical Source Material -- 15.3
Human Embryonic Stem Cell-Based Therapies -- 15.3.1 Currently

Under Clinical Evaluation -- 15.3.2 Clinically Qualified Source Materials
-- 15.4 Consensus Standards for Cell Banking -- 15.4.1 Ethics --
15.4.2 Data Standardisation -- 15.5 Basic Scientific Developments
Impacting on Quality Control and Safety -- 15.5.1 Genetic and
Epigenetic Instability Affecting Lineage and Oncogenic Potential -- 15.6
Summary -- References -- Index.
